These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 32601581)

  • 1. Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia.
    Koola MM; Praharaj SK; Pillai A
    Curr Behav Neurosci Rep; 2019 Jun; 6(2):37-50. PubMed ID: 32601581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia.
    Koola MM
    Mol Neuropsychiatry; 2018 Dec; 4(3):134-148. PubMed ID: 30643787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity.
    Koola MM; Nikiforuk A; Pillai A; Parsaik AK
    J Geriatr Care Res; 2018; 5(2):57-67. PubMed ID: 30984874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.
    Koola MM
    Prim Care Companion CNS Disord; 2018 Mar; 20(2):. PubMed ID: 29570959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.
    Koola MM; Buchanan RW; Pillai A; Aitchison KJ; Weinberger DR; Aaronson ST; Dickerson FB
    Schizophr Res; 2014 Aug; 157(1-3):84-9. PubMed ID: 24878431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine.
    Koola MM
    Schizophr Res Cogn; 2016 Jun; 4():4-9. PubMed ID: 27069875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments.
    Koola MM; Sklar J; Davis W; Nikiforuk A; Meissen JK; Sawant-Basak A; Aaronson ST; Kozak R
    Schizophr Res; 2018 Mar; 193():459-460. PubMed ID: 28705532
    [No Abstract]   [Full Text] [Related]  

  • 8. Attenuated Mismatch Negativity in Attenuated Psychosis Syndrome Predicts Psychosis: Can Galantamine-Memantine Combination Prevent Psychosis?
    Koola MM
    Mol Neuropsychiatry; 2018 Oct; 4(2):71-74. PubMed ID: 30397594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond.
    Koola MM
    Psychiatry Res; 2020 Nov; 293():113409. PubMed ID: 32829072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement.
    Koola MM; Looney SW; Hong H; Pillai A; Hou W
    Psychiatry Res; 2020 Sep; 291():113285. PubMed ID: 32763546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.
    Nikiforuk A; Potasiewicz A; Kos T; Popik P
    Behav Brain Res; 2016 Oct; 313():214-218. PubMed ID: 27435422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity.
    Lopes JP; Tarozzo G; Reggiani A; Piomelli D; Cavalli A
    Brain Behav; 2013 Mar; 3(2):67-74. PubMed ID: 23532860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
    Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia.
    Buchanan RW; Kelly DL; Weiner E; Gold JM; Strauss GP; Koola MM; McMahon RP; Carpenter WT
    J Clin Psychopharmacol; 2017 Aug; 37(4):394-400. PubMed ID: 28590362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis.
    Vayısoğlu S; Karahan S; Anıl Yağcıoğlu AE
    Turk Psikiyatri Derg; 2019; 30(4):253-259. PubMed ID: 32594486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP; Khan A
    Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice.
    Busquet P; Capurro V; Cavalli A; Piomelli D; Reggiani A; Bertorelli R
    J Pharmacol Sci; 2012; 120(4):305-9. PubMed ID: 23149577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils.
    Lorrio S; Negredo P; Roda JM; García AG; López MG
    Brain Res; 2009 Feb; 1254():128-37. PubMed ID: 19103181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.